5/29
06:30 am
nuvl
Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference
Low
Report
Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference
5/17
09:24 am
nuvl
Nuvalent, Inc. (NASDAQ: NUVL) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $99.00 price target on the stock.
Medium
Report
Nuvalent, Inc. (NASDAQ: NUVL) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $99.00 price target on the stock.
5/17
06:55 am
nuvl
FDA grants breakthrough therapy status for Nuvalent's NVL-655 [Yahoo! Finance]
Medium
Report
FDA grants breakthrough therapy status for Nuvalent's NVL-655 [Yahoo! Finance]
5/16
04:04 pm
nuvl
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655 [Yahoo! Finance]
Medium
Report
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655 [Yahoo! Finance]
5/16
04:01 pm
nuvl
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655
Medium
Report
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655
5/9
06:44 am
nuvl
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results [Yahoo! Finance]
Low
Report
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results [Yahoo! Finance]
5/9
06:30 am
nuvl
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results
Low
Report
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results
5/8
12:29 pm
nuvl
Why Earnings Season Could Be Great for Nuvalent (NUVL) [Yahoo! Finance]
Low
Report
Why Earnings Season Could Be Great for Nuvalent (NUVL) [Yahoo! Finance]
4/18
09:56 am
nuvl
Jefferies starts Nuvalent at buy, cites lung cancer drug candidates [Seeking Alpha]
Low
Report
Jefferies starts Nuvalent at buy, cites lung cancer drug candidates [Seeking Alpha]
4/17
03:01 pm
nuvl
Nuvalent, Inc. (NASDAQ: NUVL) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $97.00 price target on the stock.
Low
Report
Nuvalent, Inc. (NASDAQ: NUVL) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $97.00 price target on the stock.
4/8
04:30 pm
nuvl
Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024
Low
Report
Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024
4/2
06:21 am
nuvl
Nuvalent, Inc. (NASDAQ: NUVL) was upgraded by analysts at Leerink Partnrs from a "market perform" rating to an "outperform" rating.
Medium
Report
Nuvalent, Inc. (NASDAQ: NUVL) was upgraded by analysts at Leerink Partnrs from a "market perform" rating to an "outperform" rating.
4/1
08:10 am
nuvl
Nuvalent, Inc. (NASDAQ: NUVL) was upgraded by analysts at SVB Leerink LLC from a "market perform" rating to an "outperform" rating. They now have a $110.00 price target on the stock, up previously from $69.00.
Low
Report
Nuvalent, Inc. (NASDAQ: NUVL) was upgraded by analysts at SVB Leerink LLC from a "market perform" rating to an "outperform" rating. They now have a $110.00 price target on the stock, up previously from $69.00.
3/22
10:09 am
nuvl
Companies Like Nuvalent (NASDAQ:NUVL) Can Afford To Invest In Growth [Yahoo! Finance]
Low
Report
Companies Like Nuvalent (NASDAQ:NUVL) Can Afford To Invest In Growth [Yahoo! Finance]